Dr. Marwan G. Fakih discussed the FDA approval of Lumakras with Vectibix for third-line treatment of KRAS G12C-mutated ...
On January 7, 2025, the FDA granted priority review to the new drug application for sunvozertinib (DZD9008), an oral EGFR ...
ACLF clinical trials expected to initiate in 1Q253 clinical data readouts expected by year-end 2025 across the ACLF pipeline, including ...
Research co-led by University of Toronto researchers and Insilico Medicine has demonstrated the potential of quantum ...
Precision medicines biotech Frontier Medicines is leaving behind an unknown number of staffers as it refocuses resources to ...
Here is a select list of cancer therapies approved by the FDA throughout the month of January, featuring patient populations ...
CAYMAN ISLANDS - Silexion Therapeutics Corp. (NASDAQ: SLXN), a biotech firm focusing on RNA interference (RNAi) treatments, ...
A new study from Moffitt Cancer Center could help doctors predict how well patients with a specific type of lung cancer will ...
Alexander I. Spira, MD, PhD, FACP, discusses the next steps in the clinical development of zoldonrasib for patients with KRAS ...
Revolution Medicines' promising KRAS inhibitors show potential in pancreatic cancer. See why we recommend a hold rating on ...
Quantum computing and artificial intelligence (AI) can be combined with classical computing methods to design and discover small-molecule candidates that target the cancer-driving KRAS protein, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback